title: p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies.
abstract: In this study, we analysed immunocytochemically p53 expression in first primary and second primary cancers from 25 head and neck cancer patients (HNCPs) with multiple malignancies in comparison with oncoprotein expression in tumour tissues from 25 historical HNCP controls with single cancer in a match-paired analysis. Moreover, we investigated bleomycin-induced chromosome fragility in both groups of HNCPs and in 21 additional healthy controls. Thirty-nine out of 75 tumour specimens analysed (52%) showed positive p53 immunostaining. Eleven out of 25 (44%) from single cancer patients and 28 out of 50 (56%) tumours from HNCPs with multiple malignancies were p53 positive. In the group of multiple primary cancers, nine patients (36%) showed positive staining of both first and second primaries, whereas six (24%) had positive labelling of first primary cancer but not of the subsequent second primary, four (16%) patient showed p53 expression only in the second primary cancer and six (24%) patients showed no p53 immunoreactivity in both tumours. Chromosomal analysis demonstrated a higher sensitivity to clastogens of HNCPs with multiple tumours than of HNCPs with a single cancer (P < 0.01), and a significant correlation between chromosome fragility and p53 overexpression (P < 0.01) only in HNCPs with multiple malignancies more than in those with single head and neck cancer (P = 0.11). Moreover, we found that patients with p53-positive staining of both first and second primaries showed a statistically significant higher mutagen sensitivity than those with a single p53 immunoreactive tumour or those in whom both cancers were p53 negative (P < 0.01). Our data suggest that subjects with increased susceptibility to carcingogens after exposure to tobacco or alcohol are at higher risk for multiple cancers in which one of the most common genetic events is aberrant p53 expression.
authors.affiliation: Institute of Otolaryngology-Head & Neck Surgery, University of Florence, Italy.
authors.forename: O
authors.initials: O
authors.lastname: Gallo
authors.forename: S
authors.initials: S
authors.lastname: Bianchi
authors.forename: M L
authors.initials: ML
authors.lastname: Giovannucci-Uzzielli
authors.forename: R
authors.initials: R
authors.lastname: Santoro
authors.forename: S
authors.initials: S
authors.lastname: Lenzi
authors.forename: C
authors.initials: C
authors.lastname: Salimbeni
authors.forename: M
authors.initials: M
authors.lastname: Abbruzzese
authors.forename: E
authors.initials: E
authors.lastname: Alajmo
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000235:genetics*; D002873:Chromosome Fragility; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D016158:Genes, p53 / Q000187:drug effects*; D006258:Head and Neck Neoplasms / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009153:Mutagens / Q000633:toxicity*; D009378:Neoplasms, Multiple Primary / Q000235:genetics*; D016609:Neoplasms, Second Primary / Q000235:genetics; D012680:Sensitivity and Specificity; D012907:Smoking / Q000009:adverse effects; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D009153:Mutagens; D016159:Tumor Suppressor Protein p53